Proscia® Making News: Awards, Recognition, Patents, and New Features

Check out recent news from PACT Member, Proscia®!

Proscia® Named to 2019 CNBC Upstart 100 List of Most Promising Start-Ups to Watch – November 12, 2019

Proscia® Introduces New Enterprise-Scale Features on the Concentriq® Digital Pathology Platform for Life Sciences Companies – November 12, 2019

Proscia’s Concentriq® Dx Receives CE Mark for Primary Diagnosis – November 6

Proscia® Granted U.S. Patent for AI-Powered Dermatopathology – October 30

Proscia® Named to the 2019 CB Insights Digital Health 150 – List of Most Innovative Digital Health Startups

Proscia recognized for achievements in advancing computational pathology to improve cancer research and diagnosis.

CB Insights today named Proscia to the inaugural Digital Health 150 ranking, showcasing the 150 most promising private digital health companies in the world. CB Insights CEO Anand Sanwal revealed the final Digital Health 150 during Future of Health, a gathering of top executives across some of the largest healthcare institutions, startups, and investment firms.

“From pharmaceuticals to patient care, technology is rapidly changing healthcare, and The Digital Health 150 showcases the 150 best startups spearheading innovation and change in the sector,” said CB Insights CEO Anand Sanwal. “It’s a privilege to use CB Insights’ data to identify and shine a light on these companies, and we look forward to tracking their success in 2019 and beyond.”

Read more.

Proscia® Issued U.S. Patent Covering System and Method of Processing Medical Images for Inspection or Analysis

U.S. Patent No. 10,346,980 addresses techniques critical to the advancement of digital pathology

Proscia, a leading provider of digital pathology software, has been granted U.S. Patent No. 10,346,980 by the United States Patent and Trademark Office (USPTO). The patent applies to techniques for processing and analyzing medical images.

For more than 150 years, the standard of care for diagnosing tissue biopsies has been based on a pathologist’s interpretation of patterns using a microscope. This interpretation determines the presence of cancer as well as the aggressiveness of malignancies. Unfortunately, because this human assessment is inherently subjective, it can compromise the accuracy of diagnosis and ultimately, the success of patient outcomes.

Read more.

©2020 PACT All Rights Reserved